Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of bivalent rLP2086 meningococcal B vaccine in adolescents
2009-014493-18Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B recombinant lipoprotein 2086 vaccine in meningococcal disease and bacterial meningitis (3 arms), sponsored by Pfizer. Started Jun 2010; status: completed.
02
Drugs
meningococcal group B recombinant lipoprotein 2086 vaccine
03
Conditions
meningococcal diseasebacterial meningitis
Beyond the preview
Go deeper on 2009-014493-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014493-18.